{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal ExoFlo",
            "NStudiesAvail": 430108,
            "NStudiesFound": 9,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 9,
            "FieldList": [
                  "Acronym",
                  "AgreementOtherDetails",
                  "AgreementPISponsorEmployee",
                  "AgreementRestrictionType",
                  "AgreementRestrictiveAgreement",
                  "ArmGroupDescription",
                  "ArmGroupInterventionName",
                  "ArmGroupLabel",
                  "ArmGroupType",
                  "AvailIPDComment",
                  "AvailIPDId",
                  "AvailIPDType",
                  "AvailIPDURL",
                  "BaselineCategoryTitle",
                  "BaselineClassDenomCountGroupId",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "Acronym": [
                              "EXIT-ARDS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Saline",
                              "ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)",
                              "ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Saline",
                              "Drug: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles",
                              "Drug: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles"
                        ],
                        "ArmGroupLabel": [
                              "Placebo Saline",
                              "10mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles",
                              "15mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05127122"
                        ]
                  },
                  {
                        "Rank": 2,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Arm 1: IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 8 weeks thereafter to week 46 (n=5), (total # doses = 10).",
                              "Arm 2: IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 4 weeks thereafter to week 46 (n=5), (total # doses = 15)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Bone Marrow MSC Derived Extracellular Vesicle Isolate",
                              "Drug: Bone Marrow MSC Derived Extracellular Vesicle Isolate"
                        ],
                        "ArmGroupLabel": [
                              "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 8 weeks after that to week 46",
                              "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 4 weeks after that to week 46"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05130983"
                        ]
                  },
                  {
                        "Rank": 3,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "100ml normal saline",
                              "10ml ExoFlo + 90ml normal saline",
                              "15ml ExoFlo + 85ml normal saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ExoFlo",
                              "Drug: ExoFlo",
                              "Drug: ExoFlo"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "10ml ExoFlo",
                              "15ml ExoFlo"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05125562"
                        ]
                  },
                  {
                        "Rank": 4,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 8 weeks thereafter to week 46 (n=5), (total # doses = 10).",
                              "IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 4 weeks thereafter to week 46 (n=5), (total # doses = 15)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ExoFlo",
                              "Drug: ExoFlo"
                        ],
                        "ArmGroupLabel": [
                              "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 8 weeks after that to week 46",
                              "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 4 weeks after that to week 46"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05176366"
                        ]
                  },
                  {
                        "Rank": 5,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04657458"
                        ]
                  },
                  {
                        "Rank": 6,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Normal Saline 100 mL",
                              "Normal saline 85 mL and ExoFlo 15 mL, which is 10.5 x 10^8 EV"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Saline",
                              "Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm 1",
                              "Treatment Arm 2"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05116761"
                        ]
                  },
                  {
                        "Rank": 7,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "PLACEBO Normal saline 100 mL",
                              "IP (ExoFlo) 15ml dose in Normal saline 85 mL, which is approximately 1.2 trillion EVs."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: EXOFLO",
                              "Drug: EXOFLO"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm 1",
                              "Treatment Arm 2"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05354141"
                        ]
                  },
                  {
                        "Rank": 8,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1 AE, grade 2 skin hyperpigmentation at the infusion site, was reported; this was in DB-EF-EXPANDEDACCESS-001.\n\nClinical investigational use includes the following: Pilot study for COVID-19 IND #21669, DB-EF-PhaseII-001 (met target enrollment of N=121), and DB-EF-EXPANDEDACCESS-001 (enrolled 75 subjects; target enrollment = 100) as well as 13 single patient Emergency INDs for COVID-19 associated ARDS."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment"
                        ],
                        "ArmGroupLabel": [
                              "No SAE attributable to IP in clinical investigational use to date."
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05215288"
                        ]
                  },
                  {
                        "Rank": 9,
                        "Acronym": [
                              "EXIT-COVID19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Normal saline 100 mL",
                              "Normal saline 90 mL and ExoFlo 10 mL, which is 800 Billion Extracellular Vesicles.",
                              "Normal saline 85 mL and ExoFlo 15 mL, which is 1.2 Trillion Extracellular Vesicles."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Intravenous normal saline",
                              "Biological: DB-001",
                              "Biological: DB-001"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "Experimental Dose 1",
                              "Experimental Dose 2"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04493242"
                        ]
                  }
            ]
      }
}